Insight Molecular Diagnostics Reports Q3 2026 Revenue of $559,000, GAAP EPS of -$0. ...
FDA Review of GraftAssureDx Paused as Company Prepares Response to Additional Information Request Related Stocks: IMDX ,
FDA Review of GraftAssureDx Paused as Company Prepares Response to Additional Information Request Related Stocks: IMDX ,